Oppenheimer analyst Jay Olson initiates coverage on Acadia Pharmaceuticals (NASDAQ: ACAD) with a Perform rating, price target $44.00.The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE